Prime Medicine, Inc. (PRME) Earnings Call Transcripts

Prime Medicine, Inc.'s Latest Earnings Call - June 10, 2026

In the second quarter of fiscal year 2026, Prime Medicine, Inc. (PRME:US) provided significant updates on its clinical programs and strategic direction. The company reported progress in its chronic granulomatous disease (CGD) program, with successful genetic cures in two patients and plans for a Biologics License Application (BLA) filing. Management maintained guidance for clinical data from its Wilson disease and alpha-1 antitrypsin deficiency programs in 2027, signaling strong future growth potential. Revenue and earnings figures were not disclosed in the call, but management's confidence in their cash runway of approximately $150 million suggests stability through 2027.

Reported metrics

Guidance from management

Management maintained guidance for clinical data in 2027 for both Wilson disease and alpha-1 antitrypsin deficiency programs, indicating confidence in their timelines and development progress.

What management said

I don't know -- and there could be things out there that I haven't seen, but I don't know that I've seen any gene editing companies that have been developing in CF. I think there's maybe one collaboration I saw, but I don't know that, that program went anywhere. So we don't see much in terms of gene editing competition right now in that space.

Yes. So we have about $150 million that was last reported as of March 30. That takes us somewhere into 2027. In terms of from a program standpoint, we said data in '27. So we haven't said exactly kind of does cash get you fully through data or not. That obviously depends on a few different factors. But I would say is, again, we think about BMS, that doesn't include any milestones from BMS. It doesn't include, obvio...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape, particularly in the alpha-1 antitrypsin deficiency space where multiple gene editing approaches are being pursued. There was also inquiry about the sufficiency of data from only two patients for regulatory approval in CGD.

Main topics on the call

• Clinical Progress in CGD — Prime Medicine has successfully genetically cured two patients with chronic granulomatous disease and is moving towards a BLA filing. CEO Allan Reine stated, "we've transformed their lives really by genetically curing th...
• Upcoming Clinical Data — Management maintained guidance for clinical data from Wilson disease and alpha-1 antitrypsin deficiency programs in 2027. Reine emphasized, "we expect data in 2027," indicating a clear timeline for investors.
• Cash Runway and Financial Stability — Prime Medicine reported a cash position of approximately $150 million, which is expected to sustain operations into 2027. Reine noted, "additional capital required to get through '27 is not what I would call significant,...
• Regulatory Landscape Changes — Management highlighted a more flexible FDA environment for gene therapies, which has allowed them to reconsider the commercialization of their CGD program. Reine remarked, "the FDA was fully on board with that data packa...

Read the full Prime Medicine, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 15 Prime Medicine, Inc. earnings call transcripts on record, spanning November 14, 2023 to June 10, 2026. Based on this history, Prime Medicine, Inc. reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PRME

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

15

First call

November 14, 2023

Most recent

June 10, 2026

Reporting cadence

quarterly